Koios Care: A New Dawn in Parkinson’s Disease Management
June 17, 2025, 9:36 pm
In the world of healthcare, innovation often emerges from the most pressing challenges. Parkinson’s Disease, often dubbed the “silent pandemic,” is one such challenge. With over ten million people affected globally, the need for effective management and treatment has never been more urgent. Enter Koios Care, a Belgian-Greek healthtech startup that has recently secured €1 million in funding to revolutionize how we monitor and treat this debilitating condition.
Koios Care is not just another tech company. It’s a beacon of hope for those grappling with Parkinson’s. Founded by Dr. Konstantinos Kyritsis and Dr. Dimitris Iakovakis, the company aims to bridge the chasm between daily life and clinical care. Their innovative platform, powered by artificial intelligence, passively collects data from smartphones and smartwatches. This data transforms into actionable insights, enabling healthcare providers to make informed decisions that enhance patient outcomes.
The funding round was led by Evercurious VC, a Greek early-stage deeptech investor, with participation from Astylab Ventures and imec.istart. This financial boost will accelerate Koios Care’s mission to expand its digital health tool, ‘Parkiwatch,’ across European clinics. The tool is designed to support regulatory clearance efforts and foster partnerships with pharmaceutical companies and research institutions.
Parkinson’s Disease is more than just a collection of symptoms. It’s a complex condition that affects every aspect of a patient’s life. Traditional methods of monitoring often rely on sporadic clinic visits and self-reports, which can be unreliable. Koios Care aims to change that narrative. By leveraging real-world data, the company provides a continuous stream of information that paints a clearer picture of a patient’s condition.
Imagine a world where patients can communicate their experiences in real-time. One user of the Parkiwatch technology expressed that sometimes, under their current medication scheme, it feels like they have no Parkinson’s at all. This is not just a fleeting sentiment; it’s a glimpse into the transformative potential of personalized care. Koios Care is committed to making this a reality for everyone living with Parkinson’s.
The startup’s dual business model serves both patients and the broader healthcare ecosystem. For patients and care providers, it offers a digital health tool that enhances quality of life and drives better outcomes. For pharmaceutical and medical device companies, it serves as a robust research and development platform, generating real-world evidence that can inform therapeutic development.
The urgency of Koios Care’s mission is underscored by the growing prevalence of Parkinson’s Disease. As the medical community grapples with this “silent pandemic,” the need for continuous, objective data has never been clearer. Dr. Iakovakis emphasizes that this funding reflects an urgent need for a new standard in care. The insights generated by Koios Care empower patients to understand their condition better and equip medical teams with unprecedented information.
Koios Care is already making strides. The company has conducted a study involving 130 patients across multiple EU clinics. Their platform is currently being utilized in hospital pilot programs and by research institutions, optimizing treatment strategies. This momentum is a testament to the innovative approach that Koios Care embodies.
The potential for growth is vast. Looking ahead, Koios Care plans to develop drug-device combination products and extend its technology to address a wider range of brain and behavior-related conditions. These include Mild Cognitive Impairment, Alzheimer’s, narcolepsy, and eating disorders. In these areas, real-time, real-world monitoring remains a critical gap, and Koios Care is poised to fill it.
The company’s vision transcends borders. With roots in Greece and Belgium, Koios Care exemplifies the power of a connected European deeptech ecosystem. It’s a shining example of how scientific excellence and entrepreneurial ambition can unite to tackle pressing global challenges. The collaboration between various stakeholders—from investors to healthcare providers—creates a fertile ground for innovation.
As the healthcare landscape evolves, the importance of personalized, data-driven disease management becomes increasingly apparent. Koios Care is at the forefront of this shift. By harnessing the power of everyday devices, the company is not just improving patient outcomes; it’s reshaping the future of care for neurodegenerative disorders.
In conclusion, Koios Care stands as a testament to the potential of technology in healthcare. With its innovative approach to monitoring and treating Parkinson’s Disease, the company is not just addressing a medical need; it’s igniting hope. The journey ahead is filled with promise, and as Koios Care continues to grow, it may very well change the lives of millions. The silent pandemic is loud and clear now, and with Koios Care leading the charge, there’s a brighter future on the horizon for those affected by Parkinson’s.
Koios Care is not just another tech company. It’s a beacon of hope for those grappling with Parkinson’s. Founded by Dr. Konstantinos Kyritsis and Dr. Dimitris Iakovakis, the company aims to bridge the chasm between daily life and clinical care. Their innovative platform, powered by artificial intelligence, passively collects data from smartphones and smartwatches. This data transforms into actionable insights, enabling healthcare providers to make informed decisions that enhance patient outcomes.
The funding round was led by Evercurious VC, a Greek early-stage deeptech investor, with participation from Astylab Ventures and imec.istart. This financial boost will accelerate Koios Care’s mission to expand its digital health tool, ‘Parkiwatch,’ across European clinics. The tool is designed to support regulatory clearance efforts and foster partnerships with pharmaceutical companies and research institutions.
Parkinson’s Disease is more than just a collection of symptoms. It’s a complex condition that affects every aspect of a patient’s life. Traditional methods of monitoring often rely on sporadic clinic visits and self-reports, which can be unreliable. Koios Care aims to change that narrative. By leveraging real-world data, the company provides a continuous stream of information that paints a clearer picture of a patient’s condition.
Imagine a world where patients can communicate their experiences in real-time. One user of the Parkiwatch technology expressed that sometimes, under their current medication scheme, it feels like they have no Parkinson’s at all. This is not just a fleeting sentiment; it’s a glimpse into the transformative potential of personalized care. Koios Care is committed to making this a reality for everyone living with Parkinson’s.
The startup’s dual business model serves both patients and the broader healthcare ecosystem. For patients and care providers, it offers a digital health tool that enhances quality of life and drives better outcomes. For pharmaceutical and medical device companies, it serves as a robust research and development platform, generating real-world evidence that can inform therapeutic development.
The urgency of Koios Care’s mission is underscored by the growing prevalence of Parkinson’s Disease. As the medical community grapples with this “silent pandemic,” the need for continuous, objective data has never been clearer. Dr. Iakovakis emphasizes that this funding reflects an urgent need for a new standard in care. The insights generated by Koios Care empower patients to understand their condition better and equip medical teams with unprecedented information.
Koios Care is already making strides. The company has conducted a study involving 130 patients across multiple EU clinics. Their platform is currently being utilized in hospital pilot programs and by research institutions, optimizing treatment strategies. This momentum is a testament to the innovative approach that Koios Care embodies.
The potential for growth is vast. Looking ahead, Koios Care plans to develop drug-device combination products and extend its technology to address a wider range of brain and behavior-related conditions. These include Mild Cognitive Impairment, Alzheimer’s, narcolepsy, and eating disorders. In these areas, real-time, real-world monitoring remains a critical gap, and Koios Care is poised to fill it.
The company’s vision transcends borders. With roots in Greece and Belgium, Koios Care exemplifies the power of a connected European deeptech ecosystem. It’s a shining example of how scientific excellence and entrepreneurial ambition can unite to tackle pressing global challenges. The collaboration between various stakeholders—from investors to healthcare providers—creates a fertile ground for innovation.
As the healthcare landscape evolves, the importance of personalized, data-driven disease management becomes increasingly apparent. Koios Care is at the forefront of this shift. By harnessing the power of everyday devices, the company is not just improving patient outcomes; it’s reshaping the future of care for neurodegenerative disorders.
In conclusion, Koios Care stands as a testament to the potential of technology in healthcare. With its innovative approach to monitoring and treating Parkinson’s Disease, the company is not just addressing a medical need; it’s igniting hope. The journey ahead is filled with promise, and as Koios Care continues to grow, it may very well change the lives of millions. The silent pandemic is loud and clear now, and with Koios Care leading the charge, there’s a brighter future on the horizon for those affected by Parkinson’s.